Remus Pharma.

Why is Remus Pharmaceuticals Ltd falling/rising?

As of 11-Jun, Remus Pharmaceuticals Ltd's stock price is at 682.80, showing a slight increase of 0.34% today despite recent declines over the past week and month. The rise in investor participation suggests growing interest, contributing positively to the stock's current upward movement.

As of 11-Jun, Remus Pharmaceuticals Ltd's stock price is rising, currently at 682.80, with a change of 2.3 (0.34%) upward. This increase comes despite a recent trend of declining performance over various periods, including a 4.07% drop over the past week and a 9.50% decline over the past month. However, today’s performance is reported to be inline with the sector, indicating that the stock is not underperforming relative to its peers.<BR><BR>Additionally, there has been a notable rise in investor participation, with a delivery volume of 2.3k on June 10, which has increased by 10.58% compared to the 5-day average delivery volume. This suggests a growing interest among investors, which can contribute positively to the stock's price movement. <BR><BR>While the stock is currently above its 100-day moving average, it remains below the 5-day, 20-day, 50-day, and 200-day moving averages, indicating mixed signals regarding its short-term momentum. Nevertheless, the liquidity of the stock is sufficient for trading, as it represents 2% of the 5-day average traded value. Overall, the combination of a slight price increase today and rising investor participation appears to be driving the stock's current upward movement.

Which are the latest news on Remus Pharma.?

How big is Remus Pharma.?

As of 10th June, Remus Pharmaceuticals Ltd has a market capitalization of 813.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 255.86 Cr and Total Assets of 432.64 Cr reported as of March 2025. There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Remus Pharmaceuticals Ltd has a market capitalization of 813.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 255.86 Cr and Total Assets totaling 432.64 Cr.

Who are the peers of the Remus Pharma.?

Remus Pharma's peers include Bajaj Healthcare, Themis Medicare, Wanbury, Kopran, Sigachi Industries, Anlon Healthcare, Anuh Pharma, Kilitch Drugs, Bharat Parenter, and Shree Ganesh Rem. In terms of performance, Remus Pharma has a 1-year return of -29.38%, better than Sigachi Industries (-62.44%) but worse than Kilitch Drugs (-18.23%).

Peers: The peers of Remus Pharma. are Bajaj Healthcare, Themis Medicare, Wanbury, Kopran, Sigachi Indust., Anlon Healthcare, Anuh Pharma, Kilitch Drugs, Bharat Parenter., and Shree Ganesh Rem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Remus Pharma. and Sigachi Indust., while Average management risk is found at Bajaj Healthcare, Themis Medicare, Wanbury, Kopran, Bharat Parenter., and the rest. Growth is Excellent at Anlon Healthcare, Good at Wanbury and Remus Pharma., and Below Average at Bajaj Healthcare, Themis Medicare, Kopran, Sigachi Indust., Anuh Pharma, and the rest. Capital Structure is Excellent at Remus Pharma. and Sigachi Indust., Good at Anlon Healthcare and Kilitch Drugs, and Below Average at Bajaj Healthcare, Themis Medicare, Wanbury, Kopran, Bharat Parenter., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kilitch Drugs at -18.23%, while the peer with the lowest is Sigachi Indust. at -62.44%. Remus Pharma.'s 1-year return of -29.38% is better than Sigachi Indust. but worse than Kilitch Drugs. Additionally, peers with negative six-month returns include Sigachi Indust., Bajaj Healthcare, and Bharat Parenter.

Is Remus Pharma. technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bearish, with mixed signals from indicators like the weekly MACD and RSI, while key resistance levels remain unbroken.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD indicating a mildly bullish signal, while the moving averages on the daily chart remain bearish. The RSI shows a bullish signal on the monthly timeframe but no signal on the weekly, which adds to the mixed signals. Bollinger Bands and KST both indicate a mildly bearish stance on the weekly, and Dow Theory confirms a mildly bearish trend as well. Overall, the indicators suggest a lack of strong bullish momentum, with the price struggling below key resistance levels.

How has been the historical performance of Remus Pharma.?

Remus Pharma experienced significant growth from March 2024 to March 2025, with net sales increasing to 620.36 Cr from 212.94 Cr, and profit after tax rising to 38.42 Cr from 24.28 Cr. Key financial metrics, including earnings per share and total assets, also showed substantial improvement.

Answer:<BR>The historical performance of Remus Pharma shows significant growth from the fiscal year ending March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Remus Pharma reported net sales of 620.36 Cr, a substantial increase from 212.94 Cr in March 2024. The total operating income mirrored this growth, reaching 620.36 Cr compared to 212.94 Cr the previous year. Total expenditure also rose to 574.67 Cr from 183.98 Cr, with notable increases in the purchase of finished goods and other expenses. Operating profit (PBDIT) increased to 50.67 Cr from 31.79 Cr, while profit before tax rose to 47.34 Cr from 30.17 Cr. The profit after tax also saw an increase, reaching 38.42 Cr compared to 24.28 Cr in the prior year. The consolidated net profit for March 2025 was 29.07 Cr, up from 20.52 Cr. Earnings per share improved significantly to 24.68 from 17.45, and the book value per share adjusted to 217.2 from 134.09. On the balance sheet, total assets increased to 432.64 Cr from 333.11 Cr, and total liabilities rose to 432.64 Cr from 333.11 Cr. Cash flow from operating activities improved to 6.00 Cr from 1.00 Cr, contributing to a closing cash and cash equivalent of 7.00 Cr, up from 4.00 Cr. Overall, these metrics indicate a strong upward trend in Remus Pharma's financial performance over the year.

Is Remus Pharma. overvalued or undervalued?

As of August 28, 2025, Remus Pharma is considered undervalued with an attractive valuation grade, highlighted by a PE ratio of 36.48 and strong financial metrics, despite a year-to-date return of -28.46%.

As of 28 August 2025, Remus Pharma's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, particularly in light of its strong financial metrics. Key ratios include a PE ratio of 36.48, an EV to EBITDA of 22.82, and a PEG ratio of 0.88, which suggests that the stock is trading at a reasonable price relative to its growth potential.<BR><BR>In comparison to its peers, Remus Pharma's valuation stands out, especially against Sun Pharma, which has a PE ratio of 33.18 and is deemed expensive, and Cipla, which is also attractive with a PE of 23.65. Despite recent underperformance, with a year-to-date return of -28.46% compared to the Sensex's 3.62%, the company's strong ROCE of 63.45% and ROE of 33.47% indicate robust operational efficiency and profitability, reinforcing the case for its undervaluation.

Who are the top shareholders of the Remus Pharma.?

The top shareholders of Remus Pharma include promoter Shah Arpit Deepakkumar with 17.63%, six foreign institutional investors with a combined 4.77%, and India Emerging Giants Fund Limited as the largest public shareholder at 4.41%. Individual investors own 19.18%, with no pledged promoter holdings or mutual funds involved.

The top shareholders of Remus Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Shah Arpit Deepakkumar, owning 17.63%. Additionally, there are six foreign institutional investors (FIIs) holding a combined 4.77% of the shares. The highest public shareholder is India Emerging Giants Fund Limited, which holds 4.41%. Individual investors collectively own 19.18% of the company. Notably, there are no pledged promoter holdings and no mutual funds currently involved.

What is the bonus history of Remus Pharma.?

Remus Pharma's recent bonus history includes a 1:1 bonus announced on July 4, 2025, and a 3:1 bonus issued on June 6, 2024, rewarding shareholders with additional shares based on their existing holdings.

Remus Pharma has a notable bonus history. The most recent bonus issue was a 1:1 bonus announced with an ex-date of July 4, 2025. Prior to that, on June 6, 2024, the company issued a 3:1 bonus. This indicates that shareholders are rewarded with additional shares based on their existing holdings during these bonus issues. If you have any more questions about Remus Pharma or need further details, feel free to ask!

What does Remus Pharma. do?

Remus Pharmaceuticals Ltd is a Small Cap company in the Pharmaceuticals & Biotechnology industry, recently transitioned to public status in January 2023. Key metrics include a market cap of Rs 1,170 Cr, a P/E ratio of 40.00, and a return on equity of 33.47%.

Overview: <BR>Remus Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Small Cap company.<BR><BR>History: <BR>Remus Pharmaceuticals Ltd was originally incorporated as Remus Pharmaceuticals Private Limited in 2015. The company transitioned from a Private to Public entity and changed its name to Remus Pharmaceuticals Limited on January 06, 2023. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: Rs 1,170 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 40.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.05% <BR>Debt-Equity: -0.20 <BR>Return on Equity: 33.47% <BR>Price-to-Book: 13.50 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

When is the next results date for Remus Pharma.?

No Upcoming Board Meetings

Has Remus Pharma. declared dividend?

Remus Pharmaceuticals Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of November 19, 2024. Recent total returns show significant volatility, with a -22.04% return over the last 6 months, but a strong 253.49% return over the past 2 years.

Remus Pharmaceuticals Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 19 Nov 24<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.04%, the dividend return was 0%, resulting in a total return of -22.04%.<BR><BR>Over the past year, the price return was -6.6%, the dividend return was 0.05%, leading to a total return of -6.55%.<BR><BR>In the last 2 years, the price return was 252.22%, the dividend return was 1.27%, which resulted in a total return of 253.49%.<BR><BR>For the 3-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>In the last 4 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Over the past 5 years, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Overall, Remus Pharmaceuticals Ltd has declared a dividend, but the recent total returns indicate significant volatility, particularly in the shorter periods, with a notable decline in the last 6 months and 1 year. However, the 2-year total return shows a strong performance, suggesting potential recovery or growth in the longer term.